The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Phase I trial of LY4152199, a BAFF-R-targeting bispecific, in previously treated B-cell malignancies
In this video, Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, briefly introduces the upcoming first-in-human Phase I trial (NCT07101328) of LY4152199, a B-cell activation factor receptor (BAFF-R)-targeting bispecific antibody, in patients with previously treated B-cell malignancies. Dr Patel highlights that this trial is significant because it explores a novel target, BAFF-R, which may offer an alternative for patients who have been exposed to existing CD19- and CD20-targeting therapies. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
